Female sex is associated with a higher risk for autoimmune diseases (ADs) and immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs). While the safety of ICIs in AD cohorts has been reported, sex-segregated data on patient characteristics and outcomes are lacking. In the present study, the disease and treatment characteristics of 51 patients with cancer and preexisting AD (PAD) treated with ICIs at Bern University Hospital Cancer Center (Bern, Switzerland) between January 2017 and June 2021 were analyzed by sex. Rheumatic (n=12/27, 44.4%) and endocrine (n=11/24, 45.8%) PADs were most common among male and female patients, respectively. At the time of ICI initiation, 29.6% (n=8/27) of male and 20.8% (n=5/24) of female...
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in c...
Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhi...
Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). H...
PURPOSE Our aim is to describe the role of immune checkpoint inhibitors (ICI) in clinical practic...
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adv...
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune chec...
Evidence has recently emerged on the influence of gender on the immune system. In this systematic re...
Importance: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now s...
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for multiple ...
Background: Despite the acknowledged sex-related dimorphism in immune system response, little is kno...
Background: Patients with a history of autoimmune diseases (AIDs) have not usually been included in ...
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in c...
Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhi...
Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). H...
PURPOSE Our aim is to describe the role of immune checkpoint inhibitors (ICI) in clinical practic...
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adv...
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune chec...
Evidence has recently emerged on the influence of gender on the immune system. In this systematic re...
Importance: Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment and are now s...
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for multiple ...
Background: Despite the acknowledged sex-related dimorphism in immune system response, little is kno...
Background: Patients with a history of autoimmune diseases (AIDs) have not usually been included in ...
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in c...
Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhi...
Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). H...